Human RCT Evidence is a recurring topic in our peptide coverage. This hub collects every article tagged Human RCT Evidence, newest first, each evidence-graded and tied to real, verifiable sources.
The honest, evidence-first ranking of peptides for weight loss — the GLP-1-based incretin agonists that work in human RCTs, and the 'fat-burning' GH-fragment peptides that failed in human trials.
A clinical-evidence ranking of the peptides that actually reduce visceral (belly) fat — one of the rare peptide topics with genuine Grade A human RCT proof — separating the FDA-approved and investigational incretin/GHRH drugs from the gray-market 'fat-loss' peptides that have none.
An evidence-first ranking of the peptide drugs studied for fatty liver disease (NAFLD/MASLD) and steatohepatitis (MASH) — anchored in biopsy-confirmed human RCTs, not marketing.
A clinical-evidence ranking of the peptides marketed for insulin sensitivity and blood-sugar control — the incretin drugs that actually work in human RCTs, and the 'mitochondrial' research peptides that do not yet.
Beyond Ozempic and Wegovy: a clinical-evidence ranking of the next-generation metabolic peptides — the dual and triple incretin agonists and amylin analogues — for weight loss in 2026.
A clinical monograph on vasoactive intestinal peptide (VIP) and its synthetic form aviptadil (Zyesami/RLF-100) — a mechanistically compelling neuropeptide whose largest, best-controlled human trials in COVID-19/ARDS failed.
A clinical monograph on tirzepatide — the dual GIP/GLP-1 co-agonist sold as Mounjaro and Zepbound. Grade-A RCT evidence for diabetes, obesity and sleep apnea, with a boxed warning and a tightening 2026 compounding landscape.
A clinical monograph on thymosin alpha-1 (Zadaxin/thymalfasin) — an immune-calibrating thymic peptide with real human RCTs in hepatitis B, a negative phase 3 sepsis trial, and an unsettled 2026 US legal status.
A clinical monograph on Thymogen / oglufanide / IM-862 (Glu-Trp) — the rare bioregulator peptide tested in real human RCTs. A Grade-A negative oncology result, a Grade-B human VEGF effect, and weakly-evidenced 'immune support' claims.
A clinical monograph on tesofensine (NS2330) — the triple monoamine reuptake inhibitor sold through gray-market 'peptide' channels for weight loss. Real Phase 2 RCT data, no approval anywhere, and WADA-prohibited in 2026.
A clinical monograph on tesamorelin (Egrifta / EGRIFTA WR) — the FDA-approved GHRH analog with genuine Grade-A human RCT evidence for visceral fat in HIV lipodystrophy, and an unproven non-HIV anti-aging market.
A clinical monograph on teriparatide — recombinant human PTH(1-34), the first bone-anabolic osteoporosis drug. Grade A RCT fracture data, a clear anabolic mechanism, and a 2026 status with no controlled-substance restrictions.
A clinical monograph on survodutide (BI 456906) — the investigational once-weekly GLP-1/glucagon dual agonist. Grade A randomized evidence in obesity and MASH, but not approved anywhere as of mid-2026.
A clinical monograph on SS-31 / elamipretide (Forzinity) — the cardiolipin-binding, mitochondria-targeted tetrapeptide. First FDA-approved for Barth syndrome in 2025, yet negative on every other large trial's primary endpoint.
A clinical monograph on orforglipron — the first oral, non-peptide small-molecule GLP-1 receptor agonist, FDA-approved as Foundayo in 2026 for chronic weight management, with Grade A Phase 3 RCT evidence.
A clinical monograph on semaglutide — the long-acting GLP-1 receptor agonist behind Ozempic, Wegovy and Rybelsus. Grade-A human RCT evidence across diabetes, obesity, cardiovascular, kidney and liver disease.
A clinical monograph on retatrutide (LY3437943) — Eli Lilly's investigational triple GIP/GLP-1/glucagon agonist with the largest pharmacologic weight loss reported to date, graded A on human Phase 3 RCTs, but FDA-unapproved and WADA-prohibited as of mid-2026.
A clinical monograph on PT-141 (bremelanotide) — the centrally acting melanocortin agonist FDA-approved as Vyleesi for premenopausal HSDD. Grade-A human RCT data, a narrow label, and a real pressor and pigmentation safety profile.
A clinical monograph on pramlintide — the synthetic amylin analog and only non-insulin mealtime adjunct FDA-approved for type 1 and type 2 diabetes, with Grade-A human RCT evidence and a boxed warning for severe hypoglycemia.
A clinical monograph on oxytocin — the posterior-pituitary nonapeptide that is an FDA-approved obstetric drug (Grade A) yet a largely failed intranasal 'bonding' peptide. Two drugs, two very different evidence bases.
Human RCT Evidence is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged Human RCT Evidence, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.